Table 1 Comparison of patient background and correlation coefficient +0.4 < group and correlation coefficient + 0.4 ≧ group

Gender, N (%)

Men / women

56 (62) / 34 (38)

31 (63) / 18 (37)

25 (61) / 16 (39)

0.82^a)

Age, median (interquartile range)

68 (63, 74)

68 (62, 73)

68 (63, 74)

0.51^b)

Histological type, N (%)

adenocarcinoma

86 (96)

47 (96)

39 (95)

0.62^a)

malignant pleural mesothelioma

4 (4)

2 (4)

2 (5)

Stage, N (%)

IIIA and IIIB

27 (30)

17 (35)

10 (24)

0.56^a)

IV and recurrence

63 (70)

32 (65)

31 (76)

Performance status, N (%)

0 and 1

85 (95)

45 (92)

40 (97)

0.42^a)

2 and 3

5 (5)

4 (8)

1 (3)

Smoking history, N (%)

no smoking and current

69 (77)

34 (69)

35 (85)

0.07^a)

never

21 (23)

15 (31)

6 (15)

 Diabetes

YES / NO

18 (20) / 72 (80)

7 (14) / 42 (86)

11 (27) / 30 (73)

0.14^a)

 Hypertension

YES / NO

37 (41) / 53 (59)

19 (39) / 30 (61)

18 (44) / 23 (56)

0.62^a)

 Hyperlipemia

YES / NO

9 (10) / 81 (90)

4 (8) / 45 (92)

5 (12) / 36 (88)

0.39^a)

Body surface area (m²), median (interquartile range)

1.63 (1.49, 1.79)

1.59 (1.46, 1.68)

0.33^c)

eGFR (ml/min/1.73m²), median (interquartile range)

88 (76, 99)

76 (65, 89)

0.99^b)

Estimated Ccr (ml/min), median (interquartile range)

65 (57, 73)

58 (47, 64)

0.64^b)

eGFR≧45, <60 (ml/min/1.73m²), N (%)

4 (8)

7 (17)

0.20^a)

Scr (g/dl), median (interquartile range)

0.6 (0.5, 0.8)

0.7 (0.6, 0.8)

0.82^c)

Chemotherapy, N (%)

CBDCA+PEM+BEV

72 (80)

37 (76)

35 (85)

0.24^a)

CBDCA+PEM

18 (20)

12 (24)

6 (15)

 NSAIDs

YES / NO

18 (20) / 72 (80)

15 (31) / 34 (69)

3 (7) / 38 (93)

< 0.01^a)

 ARB

YES / NO

26 (29) / 64 (71)

12 (24) / 37 (76)

14 (34) / 27 (66)

0.31^a)

 ACEI

YES / NO

3 (3) / 87 (97)

0 (0) / 49 (100)

3 (7) / 38 (93)

0.09^a)

 PPI

YES / NO

30 (33) / 60 (67)

16 (33) / 33 (67)

14 (34) / 27 (66)

0.88^a)

Total number of treatments, median (interquartile range)

9 (6, 13)

11 (8, 14)

8 (6, 11)

< 0.01^b)